SynthesisCPT: pharmacometrics & systems pharmacology2026
Model-Based Meta-Analysis of Overall Survival in Vulnerable Platinum-Ineligible NSCLC Populations.
Synthesis in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03191786 (A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab Compared With Chemotherapy in Patients With Treatment Naïve Advanced or Recurrent), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab Compared With Chemotherapy in Patients With Treatment Naïve Advanced or Recurrent (Stage IIIb Not Amenable for Multimodality Treatment) or Metastatic (Stage IV) Non-Small Cell Lung Cancer Who Are Deemed Unsuitable for Platinum-Containing Therapy
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Model-Based Meta-Analysis of Overall Survival in Vulnerable Platinum-Ineligible NSCLC Populations.CPT: pharmacometrics & systems pharmacology · 2026Pooled it
- Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis.CPT: pharmacometrics & systems pharmacology · 2026Article
- Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IPSOS (NCT03191786) is a Phase III trial comparing atezolizumab (atezo) monotherapy to single-agent chemotherapy (gemcitabine or vinorelbine) in patients with treatment-naïve locally advanced or metastatic NSCLC unsuitable for platinum-doublet chemotherapy. The study demonstrated significant overall survival (OS) improvement in the atezo arm compared to single-agent chemotherapy, with a stratified hazard ratio (HR) of 0.78 (95% CI: 0.63-0.97; p = 0.028). Since the IPSOS control arm only allowed gemcitabine or vinorelbine, a model-based meta-analysis (MBMA) was conducted, extracting OS data from published literature in similar patients, adjusting for population differences across trials, to estimate the HR between IPSOS arms versus historical trials which utilized single-agent chemotherapies. The aim was to demonstrate the non-inferiority of the IPSOS control arm versus historical controls. The literature search included patients who were chemotherapy-naïve, had advanced or metastatic NSCLC, were platinum-ineligible, ≥ 70 years or had ECOG ≥ 2, and were treated with single-agent paclitaxel, docetaxel, gemcitabine, pemetrexed, or vinorelbine. Summary-level OS data were extracted by digitizing Kaplan-Meier curves, resulting in a database of 26 trials with 41 arms and 3637 participants. A nonparametric approach modeling the conditional probability of OS data was implemented. After adjusting for ECOG PS (the only significant covariate), the model-predicted HR for the IPSOS control arm relative to historical trials was 0.543 (95% CI: 0.435-0.677), and the HR for the IPSOS atezo monotherapy arm was 0.418 (95% CI: 0.335-0.522). Overall, the MBMA results support the benefit of atezo seen in the IPSOS trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.